Cole Liam, Fernandes Diogo, Hussain Maryam T, Kaszuba Michael, Stenson John, Markova Natalia
Malvern Panalytical Ltd., Enigma Business Park, Grovewood Road, Malvern, Worcestershire WR14 1XZ, UK.
Pharmaceutics. 2021 Apr 20;13(4):586. doi: 10.3390/pharmaceutics13040586.
Viruses are increasingly used as vectors for delivery of genetic material for gene therapy and vaccine applications. Recombinant adeno-associated viruses (rAAVs) are a class of viral vector that is being investigated intensively in the development of gene therapies. To develop efficient rAAV therapies produced through controlled and economical manufacturing processes, multiple challenges need to be addressed starting from viral capsid design through identification of optimal process and formulation conditions to comprehensive quality control. Addressing these challenges requires fit-for-purpose analytics for extensive characterization of rAAV samples including measurements of capsid or particle titer, percentage of full rAAV particles, particle size, aggregate formation, thermal stability, genome release, and capsid charge, all of which may impact critical quality attributes of the final product. Importantly, there is a need for rapid analytical solutions not relying on the use of dedicated reagents and costly reference standards. In this study, we evaluate the capabilities of dynamic light scattering, multiangle dynamic light scattering, and SEC-MALS for analyses of rAAV5 samples in a broad range of viral concentrations (titers) at different levels of genome loading, sample heterogeneity, and sample conditions. The study shows that DLS and MADLS can be used to determine the size of full and empty rAAV5 (27 ± 0.3 and 33 ± 0.4 nm, respectively). A linear range for rAAV5 size and titer determination with MADLS was established to be 4.4 × 10-8.7 × 10 cp/mL for the nominally full rAAV5 samples and 3.4 × 10-7 × 10 cp/mL for the nominally empty rAAV5 samples with 3-8% and 10-37% CV for the full and empty rAAV5 samples, respectively. The structural stability and viral load release were also inferred from a combination of DLS, SEC-MALS, and DSC. The structural characteristics of the rAAV5 start to change from 40 °C onward, with increasing aggregation observed. With this study, we explored and demonstrated the applicability and value of orthogonal and complementary label-free technologies for enhanced serotype-independent characterization of key properties and stability profiles of rAAV5 samples.
病毒越来越多地被用作基因治疗和疫苗应用中传递遗传物质的载体。重组腺相关病毒(rAAV)是一类病毒载体,目前在基因治疗的开发中受到广泛研究。为了通过可控且经济的生产工艺开发高效的rAAV疗法,从病毒衣壳设计到确定最佳工艺和制剂条件,再到全面的质量控制,都需要应对多个挑战。应对这些挑战需要适用的分析方法,以对rAAV样品进行广泛表征,包括衣壳或颗粒滴度测量、完整rAAV颗粒百分比、颗粒大小、聚集体形成、热稳定性、基因组释放和衣壳电荷,所有这些都可能影响最终产品的关键质量属性。重要的是,需要快速的分析解决方案,且不依赖于使用专用试剂和昂贵的参考标准。在本研究中,我们评估了动态光散射、多角度动态光散射和尺寸排阻色谱-多角度激光光散射联用技术在不同基因组负载水平、样品异质性和样品条件下,对广泛病毒浓度(滴度)的rAAV5样品进行分析的能力。研究表明,动态光散射和多角度动态光散射可用于确定完整和空的rAAV5的大小(分别为27±0.3纳米和33±0.4纳米)。对于名义上完整的rAAV5样品,用多角度动态光散射确定rAAV5大小和滴度的线性范围为4.4×10-8.7×10拷贝数/毫升,对于名义上空的rAAV5样品为3.4×10-7×10拷贝数/毫升,完整和空的rAAV5样品的变异系数分别为3-8%和10-37%。还通过动态光散射、尺寸排阻色谱-多角度激光光散射联用技术和差示扫描量热法推断了结构稳定性和病毒载量释放情况。rAAV5的结构特征从40°C开始发生变化,观察到聚集体增加。通过本研究,我们探索并证明了正交和互补的无标记技术在增强rAAV5样品关键特性和稳定性概况的血清型非依赖性表征方面的适用性和价值。